Aquestive Therapeutics Inc. (NASDAQ:AQST) shares traded -4.71% lower at $0.81 on Wall Street last session.
AQST stock price is now -6.89% away from the 50-day moving average and -16.84% away from the 200-day moving average. The market capitalization of the company currently stands at $42.81M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
, while ‘Lake Street’ rates the stock as ‘Buy’.
In other news, Boyd Peter E., SVP-Bus. Process & Info. Tech. bought 5,000 shares of the company’s stock on Jun 14. The stock was bought for $4,050 at an average price of $0.81. Upon completion of the transaction, the SVP-Bus. Process & Info. Tech. now directly owns 59,532 shares in the company, valued at $48220.92. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 08, Chief Executive Officer Barber Daniel bought 91,743 shares of the business’s stock. A total of $88,073 was incurred on buying the stock at an average price of $0.96. This leaves the insider owning 193,702 shares of the company worth $0.16 million. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AQST stock. A new stake in Aquestive Therapeutics Inc. shares was purchased by RICHARD W. PAUL & ASSOCIATES, LLC during the first quarter worth $1,000. In total, there are 58 active investors with 29.60% ownership of the company’s stock.
Aquestive Therapeutics Inc. (NASDAQ: AQST) opened at $0.8600 on Thursday. During the past 12 months, Aquestive Therapeutics Inc. has had a low of $0.62 and a high of $2.95. The fifty day moving average price for AQST is $0.8700 and a two-hundred day moving average price translates $0.9741 for the stock.
The latest earnings results from Aquestive Therapeutics Inc. (NASDAQ: AQST) was released for Sep, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.23, beating analysts’ expectations of -$0.31 by 0.08. This compares to -$0.37 EPS in the same period last year. The company reported revenue of $11.46 million for the quarter, compared to $13.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.73 percent. For the current quarter, analysts expect AQST to generate $10.42M in revenue.
Aquestive Therapeutics Inc.(AQST) Company Profile
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
